Corporate Presentation

Transcription

1 Corporate Presentation January NYSE AMERICAN: MTNB

2 Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company s product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as expects, anticipates, intends, plans, could, believes, estimates and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forwardlooking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under Risk Factors in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma s product candidates are all in a development stage and are not available for sale or use. 2

3 Executive Summary Next Generation Omega-3 Fatty Acid Best-in-Class Drug Delivery Platform Prescription-Only Omega-3 Fatty Acid Proprietary, disruptive lipid nano-crystal (LNC) platform technology Potential best-in-class drug in new statin-like drug class Safe, targeted intracellular delivery Demonstrated Superiority versus Vascepa in head-to-head study MAT2203 Broad-spectrum, oral antifungal QIDP + Fast Track Status LNC Pipeline Gene Therapy Focused on strategic collaborations with large, well-respected pharma and biotech companies 3 NYSE AMERICAN: MTNB Founded: 2013 Based in: Bedminster, NJ

4 - Potential Best-In-Class Drug in New Statin-Like Drug Class Demonstrated Superiority Versus Amarin s Vascepa in Head-To-Head Study Recent Events in Cardiovascular Space Provide New Opportunity for Amarin Corporation September 24, 2018: Announced positive topline cardiovascular outcomes data of Vascepa Amarin s market cap increased over 500% to ~$6 Billion following announcement : Prescription-Only Omega-3 Fatty Acid Preparations underway for Pivotal Phase 3 program in patients with very high triglycerides (VHTG) Outcomes trial not required for approval to treat VHTG Eligible for NCE 4

5 - Next Generation Prescription-Only Omega-3 Fatty Acid Specifically Designed to Treat Hypertriglyceridemia and Dyslipidemia DPA differentiates Uniquely engineered Omega-3 composition; most bioavailable Severe Hypertriglyceridemia ( 500mg/dL) High DHA HIGH number of patients with elevated triglycerides ~64M (TG 150mg/dl) DPA - Highest potency and unique MOA LOVAZA ~4M (TG 500mg/dl) Not all Rx Omega-3s are the same: EPA and DHA EPANOVA EPA and DHA Vascepa Pure EPA Low DHA 5 DHA is associated with an increase in LDL cholesterol

6 Type of Omega-3 FA Has a Unique Composition as Compared to Other Omega-3 Products Low DHA Mostly EPA+DHA Mix VASCEPA Just EPA LOVAZA Ethyl Ester EPA + DPA + HPA EPANOVA Free Fatty Acid Molecular Form 6

7 Uniquely Engineered Omega-3 Composition Importance of DPA Inversely Associated DPA is comparatively more than 8x more potent than EPA in TG reduction DPA has the unique ability to down-regulate the mrna expression of HMG CoA reductase and PCSK9 DPA DPA is a potent stimulator of endothelial cell migration DPA is a potent inhibitor of angiogenesis through inhibition of VEGFR-2 expression DPA exhibits potent TxA2 inhibition and 12-HETE production stimulation (thus reducing platelet aggregation) Inverse association between low DPA and total mortality, non-fatal MI and C-reactive protein (CRP) 7

8 Has a Unique Molecular Form Contributing to Increased Bioavailability Free Fatty Acids clinically demonstrate superior bioavailability Potential significant advantage over ethyl ester formulation for treatment of severe hypertriglyceridemia and prevention of cardiovascular events as patients expected to be on a low fat diet Correlation with significantly higher blood levels and improved efficacy in reduction of triglycerides and other biomarkers Similar results seen in head-to-head with Vascepa with 6-fold higher AUC with high statistical significance 8

9 DPA Provides Potent Fasting TG Reduction in Common Dyslipidemia Animal Model Compared to EPA Fasting TG Reduction in Fatty Zucker Rat Model Triglyceride Percent Reduction From Baseline In Vivo (N=8 per treatment group) 0% -10% -20% -30% -40% -50% -60% DPA 50 mg/kg EPA 200 mg/kg EPA 400* mg/kg EPA 1000* mg/kg 9 Source: Matinas BioPharma research; unpublished; * Approximate equivalent to 4 grams/day in humans

10 Early Data Suggests Synergy with Statin Usage Statins Induce Gene-Expression Compensatory Effects Relative Levels of mrna for HMG-CoA Reductase and PCSK9 in Rat Liver In Vivo 3 HMG-CoA Reductase 3 PCSK Vehicle Only Vehicle + Statin DPA + Statin 0 Vehicle Only Vehicle + Statin DPA + Statin Relative mrna Expression Levels in Rat Liver After 4 Weeks Dosing (400 mg DPA/kg*day) 10

11 Comparative PK/PD Study Design (Completed) 42 Patients Randomized Screening & Randomization TG mg/dl 14 day treatment 4 capsules per day Vascepa 14 day treatment 4 capsules per day 5-week washout 5-week washout Vascepa 14 day treatment 4 capsules per day 40 Patients Completed 14 day treatment 4 capsules per day Baseline Endpoint Baseline Endpoint Cross-over study design; each patient is its own control (high statistical power) Medication administered with food (life-style diet, as indicated) Patients resided in the clinic during treatment periods Steering Committee: Drs. CM Ballantyne, KC Maki, and WF Keane 11

12 Top-Line Results Comparative PK/PD Study Triglyceride Reduction (Median % Change From Baseline) 0% -5% Superior Bioavailability versus Vascepa (Primary Endpoint) approximately 6-fold higher AUC at high statistical significance -10% -15% -20% -25% -11% p < Vascepa Effects Other Lipid Parameters better than Vascepa (P<0.05) VLDL-Cholesterol Non-HDL-Cholesterol Total Cholesterol PCSK9 (significant reduction with, increase with Vascepa ) -30% -35% -33% similar to Vascepa (P=NS) LDL-cholesterol (both slightly reduced) HDL-cholesterol 12 Detailed results expected to be presented at upcoming scientific congresses and in peer-reviewed journals over the course of the year

13 Median Change, % Median Change, % Demonstrated Superiority Over Vascepa Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa Triglyceride Reduction (Median % Change From Baseline) Median % Changes from Pre-Treatment Values for Lipids Median % Changes from Pre-Treatment for Apolipoproteins and PCSK9 0% -5% -10% -15% -20% -25% -30% -35% -33% -11% p < Vascepa TG VLDL-C 1 Non-HDL-C HDL-C LDL-C 1,2 TC P < P < p = p = p = p = EPA-EE Apo B Apo AI 1 Apo CIII PCSK p = p = p = p < EPA-EE 13

14 Plasma Baseline-adjusted Total EPA (μg/ml) Blood Levels of EPA Key Element in Cardiovascular Impact Mean Plasma Baseline-adjusted Total EPA Concentration on Final Day of Treatment EPA-EE Time (Hours) from Dose 14 1: T=0 is drug administration on final day of treatment

15 World Class Clinical Development and Regulatory Team KOLs KOLS Harold Bays, M.D. Christie Ballantyne, M.D. John Kastelein, M.D., Ph.D., FESC Kevin Maki, Ph.D. FDA Regulatory Experts Internal Expertise in Omega-3 Top Global Contract Research Organization LOVAZA 15

16 - Clinical Development Timeline Next-generation, proprietary prescription-only omega-3 fatty acid Not all Omega-3s are the same: DPA and Molecular Form Differentiate Specifically designed to treat hypertriglyceridemia and dyslipidemia Uniquely engineered Omega-3 composition Superior Bioavailability DPA - Highest potency and unique MOA Proprietary delayed release gelatin capsule Discovery 2014 IND Preparation 2019 FDA Interaction and Phase 3 Finalization Late 2021 NDA Filing* Development Status: IND in process of reactivation 505(b)(2) streamlined development program Initial indication of severe hypertriglyceridemia ( 500) Options for additional development with 3 rd mover advantage 16 * Anticipated

17 Estimated Market Opportunities for New CV Drugs PCSK9s (REGN, AMGN) Hypercholesterolemia 62M Vascepa (AMRN) Hypercholesterolemia 70M 32M Treated mostly w/ Statin 30M Untreated 30M 36.5M 3.6M Borderline-High ( mg/dl) High ( mg/dl) Severely High (>500 mg/dl) 20M 10M 1.5M 0.5M LDL at goal LDL uncontrolled Refractory to statins HeFH/HoFH Bempedoic Acid (ESPR) Additional LDL Lowering Already at max. statin dose... 2M 3M 5M ~36M on statin therapy for elevated LDL M (AMRN) CVOT Study Low CV risk Medium CV Risk High CV Risk 12-13M (ESPR) (includes statinintolerant patients) 17 Source: AHA, AMA and Jefferies LLC estimates

18 Intellectual Property and Barriers to Entry Omega-3 Portfolio Filed 22 patents across 3 families Two Orange-book listable U.S. Patents issued Q US 8,906,964, Q US 10,058,521; four additional U.S. patents pending, plus opportunity for composition claims depending on outcome of USPTO debate Additional IP to be developed as clinical development plan progresses NCE Exclusivity The active moiety of is the entire mixture of omega-3 ingredients representing a single active ingredient, which makes eligible for 5-year NCE exclusivity. 18

19 Safe Intracellular Delivery of Molecules Remains a Significant Challenge LNC Platform Small molecules with poor toxicity profile Complex gene therapy molecules require intracellular delivery Cell Membrane Protective outermost layer of cell Selectively permeable Most medicines are unable to cross Diseases Exhibited by Inflammation Infectious disease Intracellular Diseases Intracellular pathogens Genetic disorders Cancer 19

20 LNCs Enable Safe, Targeted and Intracellular Delivery of Potent Medicines LNC Platform Highly Efficient, Natural and Nontoxic Drug Formulation Platform Stable lipid nano-crystal particles Prepared using naturally occurring phospholipids and calcium Captures and protects drug molecules Enter cells through non-destructive, natural membrane fusion Naturally targets immune or virally infected cells Validated in multiple clinical and preclinical studies 20

21 Effective Intracellular Delivery of a Broad Range of Molecules LNC Platform Pharmaceuticals and Biologics Small Molecules Vaccines Nucleic Acid Polymers sirna mrna Proteins Peptides CRISPR/Cas-9 DNA 21

22 LNC Platform LNC: Potential Best-In-Class Delivery System Properties Delivery Vehicles Lipid Nano-Crystal Lipid Nano-Particles Viral Vectors Rigid, solid multilayered matrix Non-aqueous interior Shelf-life stability Non-toxic Non-immunogenic Natural fusogenic intracellular delivery Flexibility of administration /- 22

23 LNC Platform Supported by Robust, Scalable Manufacturing Capacity 14,000+ sq. ft. GLP/GMP Product Development and Manufacturing Facility Located in Former Sanofi R&D Building in Bridgewater, NJ LNC Platform Includes GMP scale-up and manufacturing suites Highly scalable and reproducible manufacturing process from 1 ml to 100 liters+ Protocols developed to control and stabilize particle size ISO-8 compliant 23 Dedicated discovery lab for nucleic acid polymers, etc.

24 LNC Platform Technology Offers a New Paradigm for Drug Therapy with Broad Utility Enables Safe, Targeted Intracellular Delivery of Life-Changing Medicines LNC Platform Ability to deliver a broad range of molecules Flexible administration Oral Intravenous Intramuscular Intranasal NO evidence of immunogenicity Reduced toxicity of drugs Robust IP portfolio protection Commercially scalable 24

25 U.S. Strategy Overview Enabling Delivery of Life-Changing Medicines 25 LNC Technology Platform Highly stable lipid nano-crystals enable safe and natural intracellular delivery of: sirnas, mrna, proteins, small molecule pharmaceuticals and the potential for geneediting (CRISPR-Cas9) molecules Validated in multiple preclinical and clinical studies Differentiated from other lipid nanoparticles (stability, intracellular delivery, flexible route of administration) Building pipeline through strategic collaborations Lead Internal Development Candidate MAT2203 Orally-administered amphotericin B, a broad spectrum fungicidal drug Demonstrated to be safe and well tolerated in two Phase 2 clinical studies Recent optimization of dose volume provides commercial opportunity Evaluating additional efficacy study(ies) in treatment/prevention of invasive fungal infections (IFI) in high unmet medical need areas with opportunity for LPAD approvals

26 MAT2203: A Novel Approach to Treating Invasive Fungal Infections in Immunocompromised Patients QIDPs with Fast Track Status for Treatment of Aspergillus, Invasive Candidiasis and Prevention of IFIs MAT2203 Amphotericin B Broad Spectrum Antifungal Agent Gold Standard of treatment for immunocompromised patients Demonstrated to be Safe and Well Tolerated Multiple Phase 2 Studies No drug-related serious adverse events reported in either Phase 2 clinical study LNC Platform Technology Benefits Oral Bioavailability Reduction in toxicity and targeted delivery 26

27 MAT2203 MAT2203 Development Program Completed Studies Ph 1 SAD Study Ph 1 Food Effect Study Ph 2a Efficacy, Safety and PK Ph 2 Efficacy, Safety, PK study in women with acute VVC Toxicology healthy volunteers (N=48) 200 mg, 400 mg, 800 mg MAT2203, placebo controlled at each dose healthy volunteers (n=14) 400mg MAT2203 (N=4/16) pts w/ chronic mucocutaneous candidiasis (N=139); 200 mg, 400 mg MAT2203, fluconazole 7-day and 28-day rat & dog studies Both studies show PK within range seen in humans; safe & well tolerated at doses up to 45 mg/kg in dogs and 90 mg/kg in rats Safe at all doses; incidence of GI adverse events was dose dependent; Cmax and AUC were relatively flat with increasing doses Oral administration with a moderate-calorie, high-fat meal prolonged and increased absorption of MAT2203, resulting in a modest enhancement in systemic exposures of AMB Safe and well tolerated at 400 mg and 800 mg QD for more almost two years administered BID Met efficacy endpoint (>= 50% improvement in clinical signs & symptoms) No renal or hepatic toxicity Demonstrated dose effect in clinical response; Demonstrated MAT2203 was safe and well tolerated in 91 women with VVC at 200 mg and 400 mg per day for 5-days with no signs of the hepatic or renal toxicity often seen with IV amphotericin B. MAT2203 demonstrated 80% improvement in composite clinical score of signs and symptoms at Day 12 at 200mg PK levels consistent with observations from SAD study and NIH Ph 2a study MTD study (200, 400, 550 mg/kg/day) No signals observed; same doses being tested in on-going 90 day rat toxicology study 27

28 Clinical Development Opportunities Under Consideration INDICATION/PATHOGEN STANDARD OF CARE UNMET NEED MAT2203 POTENTIAL REGULATORY DESIGNATIONS/QUALIFICATIONS* 1 CRYPTOCOCCOSIS Amphotericin B/5FC (induction), fluconazole (maintenance) oral antifungal agent that will enable "all oral" induction in pts w/ cryptococcal meningitis; oral antifungal for maintenance in pts who develop toxicity, intolerance or drug interactions with fluconazole, or w/ infection caused by azole-resistant Cryptococcus LPAD limited indication for maintenance in pts unable to receive fluconazole 2 ENDEMIC MYCOSES (Histoplasmosis, Blastomycosis, Coccidioidomycosis, Talaromycosis) High dose fluconazole; amphotericin B (CNS only) oral antifungal agent that can be used in pts unable to receive fluconazole because of toxicity, intolerance or drug interactions LPAD limited indication for treatment in pts unable to receive fluconazole 3 PROPHYLAXIS AGAINST IFI IN ADULT ALL (ALSO AML, ALLO HCT UNABLE TO RECEIVE MOLD-ACTIVE AZOLE) None, sometimes- enchinocandins (IV only) oral antifungal agent w/ broad-spectrum coverage against yeasts and molds that can be used as prophylaxis in high-risk patients unable to receive a moldactive azole because of toxicity, intolerance or drug interactions LPAD limited indication for prophylaxis of invasive Aspergillus and Candida infections 4 INVASIVE ASPERGILLOSIS AND RARE MOLDS (SCEDOSPORIUM, FUSARIUM, ZYGOMYCOSIS) INVASIVE CANDIDIASIS Voriconazole, isavuconazole, liposomal amphotericin Echinocandin followed by fluconazole; Liposomal amphotericin (multiresistant Candida) oral antifungal agent w/ broad-spectrum coverage against molds that can be used in pts unable to receive a mold-active azole because of toxicity, intolerance or drug interactions; oral antifungal agent that can be used after initial treatment with liposomal amphotericin in pts w/ infections caused by azole-resistant Aspergillus or rare molds oral antifungal agent w/ coverage against Candida that can be used as stepdown in pts unable to receive fluconazole because of toxicity, intolerance or drug interactions; oral antifungal agent w/ coverage against azole-resistant Candida species that can be used after initial treatment with liposomal amphotericin LPAD limited indication for oral treatment in pts unable to receive a moldactive azole LPAD limited indication for oral step down treatment in pts unable to receive fluconazole PROPHYLAXIS IN LUNG TRANSPLANT PATIENTS Voriconazole oral antifungal agent w/ activity against Aspergillus that can be used in pts unable to receive voriconazole because of toxicity, intolerance or drug interactions LPAD limited indication for prophylaxis against Invasive Aspergillosis PROPHYLAXIS IN LIVER TRANSPLANT PATIENTS Fluconazole oral antifungal agent w/ activity against Candida (including azole-resistant) that can be used in pts who are unable to receive fluconazole because of intolerance or drug interactions LPAD limited indication for prophylaxis against Invasive Candidiasis LEISHMANIASIS VISCERAL OR MUCOCUTANEOUS IV ambisome, PO ketoconazole, miltefosine (new) oral antifungal agent w/ activity against Leishmania species that can be used in pts who failed prior treatment or are unable to receive ketoconazole (or miltefosine) because of intolerance or drug interactions LPAD limited indication for prophylaxis against Invasive Candidiasis in pts who are unable to receive fluconazole 28 *All indication/pathogens may qualify for orphan drug designations and all except Leishmaniaisis may qualify for QIDP / Fast track designations

29 MAT2501 Targeting NTM and Drug-Resistant Gram Negative Bacterial Infections MAT2501 MAT2501 formulates the broad-spectrum aminoglycoside amikacin into our LNC technology Active IND for the treatment of Non-Tuberculous Mycobacterium (NTM) infections (environmentally transmitted organisms) Chronic lung infection with similar course of progression as Tuberculosis Approximately 50,000 to 90,000 patients in the US; 40% refractory to treatment IV amikacin used as add-on therapy in refractory patients Demonstrated efficacy in pre-clinical models of disseminated NTM and pulmonary NTM infections, as well as biofilm models of NTM MAT2501 received QIDP and Orphan Drug designations from FDA Insmed (INSM) just received approval for inhaled amikacin to treat NTM Market Cap > $1.25 Billion 29

30 MAT2501: Cystic Fibrosis Mouse Model Lung Target Mycobacteria Colorado State University: Dr. Diane Ordway, Principal Investigator In the cystic fibrosis lung, infections by intracellular pathogens, such as intracellular mycobacteria, are problematic to treat due to a thick buildup of mucous in the lung, as well as the difficulty of many anti-microbial agents, such as amikacin, to penetrate across the plasma membranes of infected cells Oral administration of amikacin-lncs safely and effectively treat mycobacteria infections in a mouse model on cystic fibrosis Bacterial Counts in the Lungs Spleen Liver Day 84 Control (n=2) 7.21± ± ±0.03 Amikacin (AMI), 150 mg/kg QD (n=4) 3.76± ± ±0.07 Clarithromycin 250 mg/kg QD (n=5) 5.11± ± ±0.07 AmK-LNC 50 mg/kg BID (n=5) 3.68± ± ±0.01 AmK-LNC 100 mg/kg BID (n=4) 2.97± ± ±0.06 Lung Pathology 30

31 MAT2501 has High Differentiation Potential in a Rapidly Evolving Anti- Infective Arena MAT2501 has the Potential to be the First Oral Aminoglycoside Evaluating Strategic Partnership Options NTM Infections: MAT2501 Next Step: Multiple-Ascending Dose Phase 1 Study Lung, refractory to guideline therapy M. abscessus Cystic Fibrosis Preclinical screening work in drug-resistant gram negative infections: e.g. UTI, pneumonia, Acinetobacter, E. coli, Kliebsiella Potential to bring a new class of antibiotics into the community setting, while reducing hospitalization costs 31

32 Leadership Team Executive Officers Jerome D. Jabbour Chief Executive Officer, Director Keith A. Kucinski, CPA, MBA Chief Financial Officer Board of Directors Herbert Conrad Chairman of the Board Patrick G. LePore Vice Chairman Eric J. Ende, MBA, MD Director Matthew A. Wikler, MD, MBA FIDSA Director Theresa Matkovits, PhD Chief Development Officer Raphael J. Mannino, PhD Chief Scientific Officer Adam Stern Director James S. Scibetta Director Jerome D. Jabbour Chief Executive Officer, Director 32

33 Scientific Advisors Cardiovascular Christie M. Ballantyne, MD, PhD, FACC, FNLA Baylor College of Medicine, Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center, Lipid Metabolism and Atherosclerosis Clinic at Houston Methodist Hospital Harold E. Bays, MD Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Clinical Lipidology, and Diplomate of the American Board of Obesity Medicine; Founder of Your Body Goal, where he oversees a state-of-the art weight management program and also serves as Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center John J.P. Kastelein, MD, PhD, FESC Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam Kevin Maki, PhD, FNLA DePaul University, Midwest Center for Metabolic & Cardiovascular Research, Great Lakes Clinical Trials, National Lipid Association s Expert Panel 33

34 Scientific Advisors Anti-Fungal J. Carl Craft, MD - Chair Former Chief Scientific Officer for Medicines for Malaria Venture (MMV) Former Venture Head at Abbott Laboratories Anti-Infective Development Group Prof. Oliver Cornely, MD, FACP, FIDSA Head of Translational Platform, Principal Investigator, Clinical Trials Center Cologne President of the European Confederation of Medical Mycology Dimitrios P. Kontoyiannis, MD, MS, ScD, PhD (Hon),FACP, FIDSA, FECMM The Texas 4000 Distinguished Endowed Professor For Cancer Research, Department of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Frances King Black Endowed Professor, Department of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Deputy Head Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Peter G. Pappas, MD, FACP Professor of Medicine in the Division of Infectious Diseases and Tinsley Harrison Clinical Scholar at the University of Alabama in Birmingham Principal Investigator for the Mycoses Study Group David S. Perlin, PhD Internationally renowned expert in infectious disease, with primary expertise in fungal infections and mechanisms of antifungal drug resistance Executive Director of the Public Health Research Institute (PHRI) Professor of Microbiology, Biochemistry and Molecular Genetics at New Jersey Medical School Public Health Research Institute 34

35 Executing Strategy to Maximize Value of Late-Stage Clinical Assets and LNC Platform Technology Potential best-in-class drug in new statin-like drug class High value LNC clinical-stage MAT2203 Proprietary, disruptive lipid nano-crystal (LNC) platform technology Partnership opportunities Strong leadership Robust IP portfolio protection 35

36 Corporate Presentation NYSE AMERICAN: MTNB